ASX - By Stock
|
IXC |
Re:
Ann: Change in substantial holding
|
|
arkangel256
|
7 |
2.2K |
2 |
29/11/23 |
29/11/23 |
ASX - By Stock
|
7
|
2.2K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change in substantial holding
|
|
arkangel256
|
7 |
2.2K |
0 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
7
|
2.2K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
arkangel256
|
82 |
23K |
4 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
82
|
23K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Proposed Capital Return to Shareholders of $14.0 Million
|
|
arkangel256
|
82 |
23K |
3 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
82
|
23K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Becoming a substantial holder
|
|
arkangel256
|
17 |
5.9K |
4 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
17
|
5.9K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Becoming a substantial holder
|
|
arkangel256
|
17 |
5.9K |
5 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
17
|
5.9K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change of Director's Interest Notice
|
|
arkangel256
|
8 |
2.1K |
0 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
8
|
2.1K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Change of Director's Interest Notice
|
|
arkangel256
|
8 |
2.1K |
4 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
8
|
2.1K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to close IIH Evolve Phase III Clinical Trial
|
|
arkangel256
|
41 |
9.2K |
6 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
41
|
9.2K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Trading Halt
|
|
arkangel256
|
18 |
4.6K |
12 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
18
|
4.6K
|
12
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
arkangel256
|
29 |
9.8K |
3 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
29
|
9.8K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
arkangel256
|
77 |
20K |
5 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
arkangel256
|
77 |
20K |
9 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
9
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
arkangel256
|
77 |
20K |
3 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Director Resignations and Appointment of Non-Executive Chair
|
|
arkangel256
|
77 |
20K |
7 |
03/07/23 |
03/07/23 |
ASX - By Stock
|
77
|
20K
|
7
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Phase III Clinical Trial Update and New IIH Market Analysis
|
|
arkangel256
|
224 |
52K |
27 |
28/06/23 |
28/06/23 |
ASX - By Stock
|
224
|
52K
|
27
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex Granted European Orphan Drug Designation for TBI
|
|
arkangel256
|
74 |
16K |
19 |
25/06/23 |
25/06/23 |
ASX - By Stock
|
74
|
16K
|
19
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex Granted European Orphan Drug Designation for TBI
|
|
arkangel256
|
74 |
16K |
16 |
24/06/23 |
24/06/23 |
ASX - By Stock
|
74
|
16K
|
16
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex Granted European Orphan Drug Designation for TBI
|
|
arkangel256
|
74 |
16K |
21 |
23/06/23 |
23/06/23 |
ASX - By Stock
|
74
|
16K
|
21
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
arkangel256
|
219 |
44K |
6 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
219
|
44K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
arkangel256
|
241 |
46K |
2 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
241
|
46K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
arkangel256
|
241 |
46K |
2 |
26/02/23 |
26/02/23 |
ASX - By Stock
|
241
|
46K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
arkangel256
|
241 |
46K |
1 |
26/02/23 |
26/02/23 |
ASX - By Stock
|
241
|
46K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
arkangel256
|
241 |
46K |
0 |
25/02/23 |
25/02/23 |
ASX - By Stock
|
241
|
46K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
arkangel256
|
241 |
46K |
4 |
25/02/23 |
25/02/23 |
ASX - By Stock
|
241
|
46K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
arkangel256
|
241 |
46K |
5 |
04/02/23 |
04/02/23 |
ASX - By Stock
|
241
|
46K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Fundamental Analysis Discussion Only (IXC Thread)
|
|
arkangel256
|
40 |
9.1K |
11 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
40
|
9.1K
|
11
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex Receives Approval for Paediatric Plan from the EMA
|
|
arkangel256
|
132 |
20K |
2 |
15/12/22 |
15/12/22 |
ASX - By Stock
|
132
|
20K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Update - Notification regarding unquoted securities - IXC
|
|
arkangel256
|
3 |
825 |
5 |
08/12/22 |
08/12/22 |
ASX - By Stock
|
3
|
825
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notification regarding unquoted securities - IXC
|
|
arkangel256
|
27 |
3.1K |
1 |
05/12/22 |
05/12/22 |
ASX - By Stock
|
27
|
3.1K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: First Patient Randomised in IIH EVOLVE Phase III Trial
|
|
arkangel256
|
55 |
9.7K |
5 |
21/11/22 |
21/11/22 |
ASX - By Stock
|
55
|
9.7K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
arkangel256
|
30 |
5.3K |
4 |
24/10/22 |
24/10/22 |
ASX - By Stock
|
30
|
5.3K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to Present at Virtual ASX Small and Mid-Cap Conference
|
|
arkangel256
|
16 |
3.7K |
2 |
20/09/22 |
20/09/22 |
ASX - By Stock
|
16
|
3.7K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex to Present at Virtual ASX Small and Mid-Cap Conference
|
|
arkangel256
|
16 |
3.7K |
7 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
16
|
3.7K
|
7
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
arkangel256
|
47 |
13K |
2 |
09/09/22 |
09/09/22 |
ASX - By Stock
|
47
|
13K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
arkangel256
|
47 |
13K |
8 |
02/09/22 |
02/09/22 |
ASX - By Stock
|
47
|
13K
|
8
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
arkangel256
|
47 |
13K |
8 |
21/08/22 |
21/08/22 |
ASX - By Stock
|
47
|
13K
|
8
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex receives IND approval
|
|
arkangel256
|
47 |
13K |
6 |
20/08/22 |
20/08/22 |
ASX - By Stock
|
47
|
13K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Trading Halt
|
|
arkangel256
|
39 |
7.4K |
6 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
39
|
7.4K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Trading Halt
|
|
arkangel256
|
39 |
7.4K |
6 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
39
|
7.4K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
MST Financial IXC Presentation - July 14th 2022
|
|
arkangel256
|
33 |
7.1K |
5 |
06/08/22 |
06/08/22 |
ASX - By Stock
|
33
|
7.1K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Lilly's Mounjaro
|
|
arkangel256
|
13 |
2.6K |
3 |
02/07/22 |
02/07/22 |
ASX - By Stock
|
13
|
2.6K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Lilly's Mounjaro
|
|
arkangel256
|
13 |
2.6K |
3 |
02/07/22 |
02/07/22 |
ASX - By Stock
|
13
|
2.6K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex Receives UK Approval to Commence Phase III Trial
|
|
arkangel256
|
9 |
2.4K |
17 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
9
|
2.4K
|
17
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
arkangel256
|
110 |
17K |
2 |
18/06/22 |
18/06/22 |
ASX - By Stock
|
110
|
17K
|
2
|
|
ASX - By Stock
|
FFX |
Re:
General discussion
|
|
arkangel256
|
9.8K |
3.2M |
1 |
18/06/22 |
18/06/22 |
ASX - By Stock
|
9.8K
|
3.2M
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
arkangel256
|
110 |
17K |
7 |
16/06/22 |
16/06/22 |
ASX - By Stock
|
110
|
17K
|
7
|
|
ASX - By Stock
|
IXC |
Re:
The path to a Billion Dollar + company
|
|
arkangel256
|
287 |
56K |
6 |
28/05/22 |
28/05/22 |
ASX - By Stock
|
287
|
56K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
ClinicalTrials.gov - IHH EVOLVE - We are in the system !
|
|
arkangel256
|
28 |
6.6K |
5 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
28
|
6.6K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
The path to a Billion Dollar + company
|
|
arkangel256
|
287 |
56K |
5 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
287
|
56K
|
5
|
|